Beta
Sulfonylureas (e.g. glimepiride, glipizide, gliclazide)
medication Under reviewSulfonylureas are a class of oral prescription medications used primarily to lower blood glucose in adults with Type 2 diabetes. Glimepiride, glipizide, and gliclazide are second‑generation agents that are widely prescribed due to their potency and relatively predictable effects. They are not dietary supplements, and they are not indicated for people without diabetes. These drugs work by binding to ATP‑sensitive potassium channels on pancreatic beta cells, leading to membrane depolarization, calcium influx, and increased insulin secretion. This mechanism raises circulating insulin levels independent of food intake, which helps reduce fasting and post‑meal glucose. Sulfonylureas may also modestly enhance peripheral insulin sensitivity and reduce glucagon secretion, further contributing to lower blood sugar. In clinical practice, glimepiride, glipizide, and gliclazide are used as monotherapy or in combination with other glucose‑lowering drugs to improve glycemic control, typically lowering HbA1c by about 1–2 percentage points. They are considered low‑cost options but carry a notable risk of hypoglycemia, especially when meals are missed, doses are high, or kidney function is impaired. Gliclazide and glipizide are often chosen in patients with renal impairment because they have a somewhat lower hypoglycemia risk compared with older sulfonylureas.
Research summary
Human research on sulfonylureas focuses almost entirely on adults with Type 2 diabetes rather than healthy volunteers. Randomized trials and large observational cohorts consistently show that glimepiride, glipizide, and gliclazide effectively reduce HbA1c and fasting glucose and can be comparable to insulin as initial therapy in some patients. Head‑to‑head comparisons suggest similar glucose‑lowering efficacy among these agents, with some evidence that modern preparations of gliclazide may have fewer hypoglycemic episodes than glimepiride in typical diabetic populations. Safety data indicate that hypoglycemia is the principal adverse effect, and the risk increases with higher doses, missed meals, exercise, and reduced kidney function. Cardiovascular outcome analyses generally do not show major differences in overall mortality between individual sulfonylureas, though some data suggest glimepiride may be preferable in people with established coronary artery disease. Because these medications stimulate insulin release regardless of blood sugar level, they are not recommended for healthy individuals as a performance or longevity aid, and using them without diabetes would pose a significant risk of dangerous low blood sugar.
Reported Benefits
No reports yet
Be the first to report this effect and help the community.
Add Sulfonylureas (e.g. glimepiride, glipizide, gliclazide) to your stack to report effects
The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Sulfonylureas Monotherapy
Simpson SH, Lee J, et al.
No reports yet
Be the first to report this effect and help the community.
Add Sulfonylureas (e.g. glimepiride, glipizide, gliclazide) to your stack to report effects
The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Sulfonylureas Monotherapy
Simpson SH, Lee J, et al.
No reports yet
Be the first to report this effect and help the community.
Add Sulfonylureas (e.g. glimepiride, glipizide, gliclazide) to your stack to report effects
Clinical Practice Does Not Confirm Superiority of Gliclazide Over Other Sulfonylureas in Reducing Hypoglycaemia
van Dalem J, et al.
No reports yet
Be the first to report this effect and help the community.
Add Sulfonylureas (e.g. glimepiride, glipizide, gliclazide) to your stack to report effects
Clinical Practice Does Not Confirm Superiority of Gliclazide Over Other Sulfonylureas in Reducing Hypoglycaemia
van Dalem J, et al.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Related health conditions
Research showing how this habit affects specific health conditions. Always consult healthcare professionals.
May Help With
Coronary artery disease or other cardiac conditions
Clinical Practice Does Not Confirm Superiority of Gliclazide Over Other Sulfonylureas in Reducing Hypoglycaemia
van Dalem J, et al.
Metabolic disorder characterized by high blood sugar and insulin resistance
The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Sulfonylureas Monotherapy
Simpson SH, Lee J, et al.
Clinical Practice Does Not Confirm Superiority of Gliclazide Over Other Sulfonylureas in Reducing Hypoglycaemia
van Dalem J, et al.
Research (2 studies)
Clinical Practice Does Not Confirm Superiority of Gliclazide Over Other Sulfonylureas in Reducing Hypoglycaemia
van Dalem J, et al.
The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Sulfonylureas Monotherapy
Simpson SH, Lee J, et al.
Community updates
No updates yet for this supplement.
Be the first to share your experience!